If you have been reading about pentapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
=== Management === No agents of biological pest control are used against the lesser mealworm. The fungus Beauveria bassiana is an arthropod pathogen that may prove useful. Some protozoa and spider species are known natural predators. Control is usually attempted with carbaryl insecticide in the form of powder, liquid, and bait. Thiamethoxam and 9-Tricosene used in conjunction have been shown to be successful in poultry houses. Pyrethroids and boric acid are used. True outbreaks are often uncontrollable and some populations of the beetle have shown resistance to various compounds. Resistance is more common on farms that have been chemically treated for many years. Insecticides are not ideal because they contaminate the poultry and they are not effective on the pest when it burrows out of reach. Proper maintenance of poultry housing usually keeps the beetle under control, as it propagates in accumulated litter and droppings.
== Early life and education == David Andrew Sinclair was born in Australia in 1969 and grew up in St Ives, New South Wales. His paternal grandmother had emigrated to Australia following the suppression of the Hungarian Uprising of 1956, and his father changed the family name from Szigeti to Sinclair. Sinclair studied at the University of New South Wales, Sydney, obtaining a bachelor of science in biochemistry in 1991 and a Ph.D. in molecular genetics in 1995, focusing on gene regulation in yeast. He also won the Australian Commonwealth Prize.
transactivation An experimental approach to artificially control gene expression by introducing a transactivator gene under the control of an inducible promoter into a genome. The transactivator encodes a transcription factor capable of acting in trans upon one or more other genes by recognizing and specifically binding their promoters; thus by inducing the transactivator gene, the expression of many other genes can be experimentally manipulated.
=== Night flight === It has been suggested that C. vomitoria rarely fly at night, regardless of the presence of an existing corpse. They thus may not deposit eggs on corpses during the night. This is relevant for forensic science, as the approximate time of oviposition would be during the daytime.
=== Newborn screening === On May 9, 2014, the UK National Screening Committee (UK NSC) announced its recommendation to screen every newborn baby in the UK for four further genetic disorders as part of its NHS Newborn Blood Spot Screening programme, including maple syrup urine disease. The disease is estimated to affect 1 out of 185,000 infants worldwide and its frequency increases with certain heritages. Newborn screening for maple syrup urine disease involves analyzing the blood of 1–2 day-old newborns through tandem mass spectrometry. The blood concentration of leucine and isoleucine is measured relative to other amino acids to determine if the newborn has a high level of branched-chain amino acids. Once the newborn is 2–3 days old the blood concentration of branched-chain amino acids like leucine is greater than 1000 μmol/L and alternative screening methods are used. Instead, the newborn's urine is analyzed for levels of branched-chain alpha-hydroxyacids and alpha-ketoacids. Other diagnostic methods include additional laboratory studies which include gas and liquid chromatography, BCKAD (branched-chain alpha-keto acid dehydrogenase) enzyme activity, dinitrophenylhydrazine (DNPH) test, and molecular testing. Gas chromatography-mass spectrometry, urine test strips and the DNPH test can detect urinary organic acid that supports the diagnosis of MSUD. Branched-chain-ketoacids can be detected by the DNPH test, where the DNPH reagent and urine get mixed equally and are observed for ten minutes to see color and precipitation changes.
Sources: en.wikipedia.org
These two factors, β and DNF, are almost the same thing, but not quite; they differ in the case a rapid (faster than the decay time of the precursor atoms) change in the number of neutrons in the reactor. Another concept is the effective fraction of delayed neutrons βeff, which is the fraction of delayed neutrons weighted (over space, energy, and angle) on the adjoint neutron flux. This concept arises because delayed neutrons are emitted with an energy spectrum more thermalized relative to prompt neutrons. For low enriched uranium fuel working on a thermal neutron spectrum, the difference between the average and effective delayed neutron fractions can reach 50 pcm.
After details of past social media posts made by two Reform UK candidates, Lee Bunker and Angela Begbie-Carter, are reported in the media, the party releases a statement in which it says candidates are free to express views that "are not shared by all their party colleagues" as they are not "political zombies". Secret government files seen by BBC News show work has been underway with consultants since January to limit "severe implications" to essential IT services by lining up alternative providers after Atos, the UK subsidiary of which has contracts for NHS records and disability benefit claims, is more than £3bn in debt and undergoing restructuring. Sinn Féin launches its 2024 election manifesto, which includes plans for the transfer of fiscal powers from Westminster to Stormont and the creation of an all-Ireland national health service. Businessman Zia Yusuf donates an undisclosed amount of money, but reported to be several thousand pounds, to Reform UK, saying the UK has "lost control of our borders". The Workers Party of Britain launches its election manifesto, with promises to improve "poverty pay" and provide more social housing. BBC News reports that Laura Saunders, the Conservative candidate for Bristol North West, has become the second Conservative candidate to face an investigation by the Gambling Commission over betting on the date of the general election. It is subsequently reported that her husband, Tony Lee, the Conservative Party's campaigns director, is also being investigated by the Commission.
A fuel rod is reprocessed after three years of use to remove waste products, which by then account for 3% of the total weight of the rods. Any uranium or plutonium isotopes produced during those three years are left and the rod goes back into production. The presence of up to 1% gallium per mass in weapons-grade plutonium alloy has the potential to interfere with long-term operation of a light water reactor. Plutonium recovered from spent reactor fuel poses little proliferation hazard, because of excessive contamination with non-fissile plutonium-240 and plutonium-242. Separation of the isotopes is not feasible. A dedicated reactor operating on very low burnup (hence minimal exposure of newly formed plutonium-239 to additional neutrons which causes it to be transformed to heavier isotopes of plutonium) is generally required to produce material suitable for use in efficient nuclear weapons. While "weapons-grade" plutonium is defined to contain at least 92% plutonium-239 (of the total plutonium), the United States have managed to detonate an under-20Kt device using plutonium believed to contain only about 85% plutonium-239, so called '"fuel-grade" plutonium. The "reactor-grade" plutonium produced by a regular LWR burnup cycle typically contains less than 60% Pu-239, with up to 30% parasitic Pu-240/Pu-242, and 10–15% fissile Pu-241. It is unknown if a device using plutonium obtained from reprocessed civil nuclear waste can be detonated, however such a device could hypothetically fizzle and spread radioactive materials over a large urban area.
Furthermore, it was shown that the codons do not overlap with each other in the DNA sequence encoding a protein, and that each sequence is read from a fixed starting point. To actually decipher the code, it took an extensive series of experiments in biochemistry and bacterial genetics, between 1961 and 1966—most importantly the work of Nirenberg and Khorana. During 1962–1964, numerous conditional lethal mutants of a bacterial virus were isolated. These mutants were used in several different labs to advance fundamental understanding of the functions and interactions of the proteins employed in the machinery of DNA replication, DNA repair, DNA recombination, and in the assembly of molecular structures.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
肽键在 214 nm 附近有较强吸收，适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。